Businesses For Sale

Global DX Limited

Download Information 

SIA Group are excited to present a unique opportunity to acquire intellectual property assets of Global DX Limited (in Administration), an innovative in-vitro diagnostics company specialising in cutting-edge disease testing for animals.

Since its incorporation in 2017, the Company has developed a suite of diagnostic antibody tests for the effective and reliable detection of African Swine Fever (ASF), including a fully developed rapid lateral flow test which has been evaluated by a number of world-renowned research institutes and has been proven to significantly outperform other commercially available assays in the detection of ASF.

This test is underpinned by the Company’s proprietary Direct Sample Conjugation (DSC) technology, which has several advantages over standard lateral flow tests, including greater sensitivity, reduced production time and costs, greater durability and longer shelf life, along with several advantages over lab-based tests, including rapid deployment and ease of use, which is critical in preventing outbreaks in areas with limited infrastructure. DSC also has potential to be utilised in other lateral flow tests to diagnose infectious diseases in both humans and animals, including COVID-19 and avian flu (H5N1) tests. In addition, DSC has potential application across the wider medical diagnostic field, including in pregnancy tests and troponin cardiac tests, along with the environmental monitoring and food safety industries.

Opportunity Highlights

- Opportunity to access the growing animal diagnostics market and capitalise upon the increasing global focus on animal health and biosecurity
- Transformative DSC technology with the potential to become the gold standard for the next generation of human and animal rapid lateral flow tests
- Significant licensing potential through wider application of DSC technology, including pregnancy and troponin cardiac tests

Assets for Sale

- Rights to a fully developed ASF antibody test and accompanying DSC technology
- Rights to a near-developed gold colloid ASF antibody test currently undergoing stability
testing
- Extensive technical records and lab data
- Organisational knowledge including manufacturing guides, manuals and instructions for use
- Registered trade mark portfolio

Interested parties are requested to deal specifically with Emily Muir and Emre Turan at SIA Group. Further information including access to a virtual data room can be provided upon execution of an NDA. It is intended that a sale will be executed at the earliest opportunity and all expressions of interest must be registered by no later than Tuesday 4th March 2025 at 12pm (GMT).